For immediate release
Contact person: Oliver Liu
Company name: Radiant Genomics, Inc.
Radiant Genomics, Inc. Awarded an SBIR Phase I Grant
Emeryville, CA, November 20, 2014 – Radiant Genomics, Inc. is pleased to announce it has been awarded a Phase I Small Business Industrial Research (SBIR) grant from the National Institute of General Medical Sciences, part of the National Institutes of Health, for the project titled “A Web-Enabled Database for Rapid Metagenomic Biocatalyst Discovery and Validation.”
“We are pleased with the continued support from the NIH towards our efforts to mine the metagenome for industrial and pharmaceutical value,” said Dr. Jeffrey Kim, CSO of Radiant Genomics, Inc. “With this grant award, Radiant can begin development of its Enzyme Variant Engine (EVE) platform. EVE will be a valuable service not just for scientists involved in synthetic pathway engineering, but basically for all molecular biologists in both industry and academia. In just about every way, EVE will be a superior alternative to current gene synthesis technologies. We are incredibly excited to begin building EVE. We expect to roll out a beta-version of the service in early 2015.”
About the Company
Radiant Genomics, Inc. was founded in 2012 with the goal of integrating a range of novel technologies including large-scale sequencing, synthetic biology, bioinformatics, cloud computing, metabolic engineering, and high-throughput analytical chemistry to develop a robust industrial platform for natural product discovery, diversification, and production. Radiant Genomics utilizes this platform to develop products in numerous market categories including pharmaceuticals, agriculture, specialty chemicals, and nutraceuticals.